Omrix claims US first for fibrin sealant:
This article was originally published in Clinica
Executive Summary
Omrix biopharmaceuticals has launched in the US what it claims to be the country's first commercially available liquid fibrin sealant that does not include any animal-derived components. The product, called Crosseal, is approved by the FDA as an adjunct to haemostasis in liver surgery. It requires no reconstitution and can be prepared for use in less than a minute, says the Brussels, Belgium-based firm. The sealant is being sold in the US by the American Red Cross Plasma Services, which formed a long-term marketing and distribution deal with Omrix earlier this year. Omrix markets a similar product, Quixil, in Europe, Latin America and Israel.
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.